Nxera Pharma & Santhera Pharmaceuticals

Nxera Pharma: Nxera Pharma holds exclusive rights to AGAMREE in Japan, South Korea, Australia, and New Zealand, and plans to submit a Marketing Authorization Application in South Korea during 2026. This designation will accelerate the review process for AGAMREE.

Santhera Pharmaceuticals: Santhera Pharmaceuticals will receive sales, milestone payments, and royalties from the net sales of AGAMREE in South Korea, Japan, Australia, and New Zealand due to the licensing agreement with Nxera Pharma The Orphan Drug Designation and Global Innovative Products on Fast Track designation for AGAMREE in South Korea are positive developments for the company.

Nxera Pharma: Nxera reported strong Q2 results with revenue growth and profitability, driven by milestone payments and progress across its pipeline. The company's strategic partnerships and licensing deals position it for continued growth.

Santhera Pharmaceuticals: Santhera signed a licensing agreement with Nxera for vamorolone in Japan, South Korea, Australia, and New Zealand, expanding access to a Duchenne Muscular Dystrophy treatment.

Nxera Pharma: Nxera Pharma holds commercialization rights for AGAMREE in Japan, South Korea, Australia, and New Zealand. Positive clinical data could support future market expansion in its licensed territories.

Santhera Pharmaceuticals: Santhera Pharmaceuticals is the developer of AGAMREE and benefits from positive clinical trial results, which could lead to expanded indications and increased sales-based milestone payments and royalties from its licensing partners.

Nxera Pharma: Nxera Pharma holds rights for Japan, South Korea, Australia, and New Zealand; not impacted by this expansion.

Santhera Pharmaceuticals: Santhera expands its distribution network for AGAMREE, potentially increasing revenue and market access in Central Asia and the Caucasus.